Initial Risk Factors for BLPD and Influence on Survival
| Risk Factors . | Survival Rates3-150 . | Univariate Analysis (P) . | |
|---|---|---|---|
| At 3 Mo . | At 1 Yr . | ||
| Type of transplant | |||
| Marrow | 57 | 35 | ≤.05 |
| Organ | 77 | 55 | |
| No. of sites | |||
| <4 | 88 | 51 | ≤.001 |
| ≥4 | 42 | 26 | |
| Clonality3-151 | |||
| Oligo | 76 | 60 | NS |
| Mono | 62 | 34 | |
| CNS | |||
| Noninvolved | 76 | 51 | NS |
| Involved | 43 | 29 | |
| BLPD occurrence3-152 | |||
| <365 d | 69 | 50 | NS |
| ≥365 d | 50 | 22 | |
| BMT for | |||
| Immunodeficiency | 76 | 59 | ≤.005 |
| Hematological malignancies | 27 | 0 | |
| Treatment delay3-153 | |||
| <25 d | 65 | 45 | NS |
| ≥25 d | 71 | 46 | |
| B-cell abnormalities3-155 | |||
| Yes | 60 | 43 | NS |
| No | 76 | 53 | |
| Antiviral therapy¶ | |||
| Yes | 68 | 40 | NS |
| No | 68 | 50 | |
| Heavy immunosuppression# | |||
| Yes | 71 | 46 | NS |
| No | 63 | 45 | |
| Complete remission | |||
| Yes | 96 | 72 | ≤.0001 |
| No | 20 | 4 | |
| Risk Factors . | Survival Rates3-150 . | Univariate Analysis (P) . | |
|---|---|---|---|
| At 3 Mo . | At 1 Yr . | ||
| Type of transplant | |||
| Marrow | 57 | 35 | ≤.05 |
| Organ | 77 | 55 | |
| No. of sites | |||
| <4 | 88 | 51 | ≤.001 |
| ≥4 | 42 | 26 | |
| Clonality3-151 | |||
| Oligo | 76 | 60 | NS |
| Mono | 62 | 34 | |
| CNS | |||
| Noninvolved | 76 | 51 | NS |
| Involved | 43 | 29 | |
| BLPD occurrence3-152 | |||
| <365 d | 69 | 50 | NS |
| ≥365 d | 50 | 22 | |
| BMT for | |||
| Immunodeficiency | 76 | 59 | ≤.005 |
| Hematological malignancies | 27 | 0 | |
| Treatment delay3-153 | |||
| <25 d | 65 | 45 | NS |
| ≥25 d | 71 | 46 | |
| B-cell abnormalities3-155 | |||
| Yes | 60 | 43 | NS |
| No | 76 | 53 | |
| Antiviral therapy¶ | |||
| Yes | 68 | 40 | NS |
| No | 68 | 50 | |
| Heavy immunosuppression# | |||
| Yes | 71 | 46 | NS |
| No | 63 | 45 | |
| Complete remission | |||
| Yes | 96 | 72 | ≤.0001 |
| No | 20 | 4 | |
Abbreviation: NS, not significant.
The percentage of patients surviving after 3 months and 1 year.
Clonality data are available for 54 BLPD events.
In days after transplant (d).
Treatment delay in days (d) between first BLPD symptoms and initiation of anti-CD21 and anti-CD24 therapy.
B-cell abnormalities are defined as the detection of more than 120 B cells/μL or more than 100 plamocytes/μL. Data were available for 45 patients.
¶Therapy with Acyclovir (n = 16) or Ganciclovir (n = 8) or Ganciclovir + Foscavir (n = 1) at the time of anti-CD21 and anti-CD24 therapy. Twenty-five patients received antiviral therapy at the time of anti-CD21 and anti-CD24 therapy.
#Heavy immunosuppressive therapy 3 months before BLPD symptoms with ATG or OKT3 or methylprednisolone (5 mg/kg/d IV for more than 1 week) or high-dose methylprednisolone bolus (1 g/1.73 m2).